Olympus Reports Strong Q2 Growth, Raises Full-Year Guidance

Olympus Corporation delivered strong financial results for the second quarter of fiscal year 2027, reporting a 9% year-over-year increase in revenue to ¥269.2 billion, or approximately $1.7 billion. This growth, bolstered by a favorable exchange rate, prompted the company to raise its full-year revenue guidance, signaling confidence in its ongoing momentum.

The positive results were fueled by robust performance across both of its core business segments: the Gastrointestinal Solutions (GIS) division and the Surgical and Interventional Solutions (SIS) division. GIS experienced continued growth in key markets, while SIS demonstrated a recovery, benefiting from the resumption of shipments and the successful integration of the BioProtect acquisition. The SIS division’s growth was partially offset by the ongoing impact of FDA import alerts and voluntary shipment holds.

Adjusted operating profit also saw a significant increase, rising to ¥84.96 billion, representing a 38.8% year-over-year improvement. This rise was driven by increased revenue, cost efficiencies, and a positive impact from the reversal of a U.S. tariff refund. However, Olympus continues to navigate challenges related to FDA scrutiny, having received warning letters for six facilities and import alerts for certain products. Despite these hurdles, the company anticipates no material impact to its fiscal year 2027 consolidated financial results from these regulatory issues, and is actively collaborating with the FDA to address concerns and implement corrective measures.

Looking ahead, Olympus has raised its full-year revenue guidance, reflecting the strong first-half performance and an optimistic outlook. The company’s focus on innovation, strategic acquisitions like BioProtect, and operational improvements positions it for continued growth. The raised guidance underscores a strengthening financial position and a commitment to delivering value in the evolving medical technology landscape.